Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renoral is an oral amino acid supplement developed by Indigo Therapeutics specifically for the nutritional management of patients with end-stage renal disease (ESRD) who are undergoing hemodialysis. It is designed to address protein-energy wasting (PEW), a condition common in dialysis patients where protein loss and malnutrition lead to increased morbidity and mortality. Renoral is administered as a concentrated drink during the dialysis session (intradialytic), serving as an oral alternative to intravenous amino acid infusions. The formulation contains a balanced mixture of essential and non-essential amino acids intended to maintain protein homeostasis, support muscle mass, and improve the overall nutritional status of patients with chronic renal failure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Renoral.